Antiretroviral Therapy in 2010 | Open Access
Cécile L Tremblay, Jean-Guy Baril, David Fletcher, Donald Kilby, Paul MacPherson, Stephen D Shafran, Mark W Tyndall, "Challenges in Initiating Antiretroviral Therapy in 2010", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 21, Article ID 834627, 15 pages, 2010. https://doi.org/10.1155/2010/834627
Challenges in Initiating Antiretroviral Therapy in 2010
Many clinical trials have shown that initiating antiretroviral therapy (ART) at higher rather than lower CD4 T cell-positive counts results in survival benefit. Early treatment can help prevent end-organ damage associated with HIV replication and can decrease infectivity. The mainstay of treatment is either a non-nucleoside reverse transcriptase inhibitor or a ritonavir-boosted protease inhibitor in combination with two nucleoside reverse transcriptase inhibitors. While effective at combating HIV, ART can produce adverse alterations of lipid parameters, with some studies suggesting a relationship between some anti-retroviral agents and cardiovascular disease. As the HIV-positive population ages, issues such as hypertension and diabetes must be taken into account when initiating ART. Adhering to ART can be difficult; however, nonoptimal adherence to ART can result in the development of resistance; thus, drug characteristics and the patient’s preparedness to begin therapy must be considered. Reducing the pill burden through the use of fixed-dose antiretroviral drug combinations can facilitate adherence.
Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.